The mechanism of drug delivery and engineering of antibodies in cancer targeted therapy Challenges and Benefits
-
Zahra Farhoud Khomeirani,1,* Sepehr Bozorgchenani,2
1. Department of veterinary Medicine, Rasht Branch, Islamic Azad university
2. Department of Bioinformatics, Tehran branch, Science and Culture University
- Introduction: Cancer is one of the most challenging diseases and a significant cause of death in the world. Recently, cancer has been considered as one of the leading causes of death worldwide and much research has been done to overcome this public health problem. Although much effort has been made to design new chemotherapy drugs, only some of which have shown significant effects on cancer cell destruction, the inability of these drugs to distinguish between healthy and cancer cells leads to systemic toxicity and adverse side effects. Be. Also, resistance to chemotherapy is another problem with successful tumor control. To date, immunotherapy has been considered the most promising treatment for systemic cancer, compared to conventional anticancer strategies. Administration of cytokines, immunosuppressants, and monoclonal antibodies to tumor-targeting (mAbs). In this review, we will discuss drug delivery potentials, which include a range of methods to enhance immunotherapy.
- Methods: In this study of drug delivery potentials, we used Google Scholar, Pubmed, and Online Wiley databases to enhance the safety of drugs.
- Results: In addition to these benefits, however, serious toxicities characterize a wide range of immune-modulating drugs. Thus, a challenge in this area is to develop effective strategies to curb the potential of combination therapies while preventing the debilitating toxicities that prevent immune therapies from reaching their full therapeutic potential.
- Conclusion: Targeting toxic compounds to tumors has historically been pursued as a strategy to increase the efficacy and limit the systemic toxicity of cancer therapies. To this end, much effort has been made to produce nanoparticles that passively amplify the accumulation of small molecule chemotherapies and targeted drugs in tumors.
- Keywords: Cancer treatment, Antibody Monoclonal, Resistance to chemotherapy, nanoparticles
